Clinical trials: COVID-19; Immunity
COVID-19, Vaccine Reaction
Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction
The COSI BAIR trial will involve approximately 60 children, aged 5 to 8 years old, comprising a subset of participants from the Melbourne Infant Study BCG for Allergy and Infection Reduction (MIS BAIR) randomised controlled…
- Conditions
- COVID-19, Vaccine Reaction, Immunization; Infection
- Trial name
- COSI BAIR (NCT05168709)
- Testing
- Tozinameran
- Where
- Australia
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Microbiome,Immune Function, Critically Ill
Microecology and Host Immunity in Patients With Severe COVID-19 Infection
The purpose of this study was to analyze the relationship between the microbial community, host immunity and the prognosis of patients with severe COVID-19.
- Trial name
- NCT05670275
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
COVID-19, Immune Response
Immunomodulatory Effect of Probiotics on the Immunogenicity of Anti-SARS-CoV-2 Vaccines
This study aims to evaluate whether oral probiotic supplementation can modulate the immune response induced by COVID-19 vaccination.
- Trial name
- NCT07610512
- Testing
- Probiotics
- Where
- Taiwan
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Grape King Bio Ltd.
Covid19, Immunodeficiency
Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)
The first version of this preprint article is registered on the 4th of May 2020 under the digital object identifier of:10.31219/osf.io/u56fc.
- Trial name
- NCT04553705
- Testing
- Omega 3/Nigella Sativa Oil, Omega 3/Nigella Sativa Oil/Indian Costus, Omega 3/Nigella Sativa Oil/Quinine pills
- Where
- Saudi Arabia
- Volunteers
- 150 people
- Sponsor
- Beni-Suef University
Prevention of COVID-19
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
This is a randomised controlled, adaptive, multicentre Phase II protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2.
- Trial name
- EU-COVAT-1 (NCT05160766)
- Testing
- Comirnaty (BTN162b2), Spikevax (mRNA-1273)
- Where
- 9 sites in Germany, Lithuania and 2 more
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Oliver Cornely, MD
COVID-19
Study on Antibody Persistence and Immune Memory of Inactivated COVID-19 Vaccine
The study describe 1 year durability of humoral and cellular immune responses in 150 individuals who received COVID-19 inactivated vaccine. all participants were recruited aged between 18 and 59 years old.
- Trial name
- NCT05072496
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Non-hodgkin Lymphoma,B Cell, Vaccination Failure
Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma
The specific immune response to SARS-CoV-2 includes a humoral response - specific IgM appearing 5 days after the onset of symptoms while IgG appears after 14 days - and a T lymphocyte component, with specific activated CD8 and…
- Trial name
- LYMPHO-CoVac (NCT05050461)
- Testing
- Immunological analyses
- Where
- 7 sites in France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Versailles Hospital
COVID-19, Vaccination
Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases
Background: Vaccines against SARS-CoV-2, the virus that causes COVID-19, have been highly effective against preventing severe disease. But the protective effects of these vaccines appear to wane over time.
- Conditions
- COVID-19, Vaccination, Healthy Volunteer
- Trial name
- NCT05078905
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
IgM and IgG in Blood
Immune Response Following COVID-19 Vaccination
Few trials have reported the safety and efficacy of the COVID-19 vaccines. However, these trials were mostly focused on post-vaccination adverse events and short-term antibody detection with none monitoring the presence of…
- Trial name
- IFVAC (NCT04736524)
- Testing
- Rapid antibody test
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Texas Cardiac Arrhythmia Research Foundation
Covid19
Evaluation and Longitudinal Follow-up of Biomarkers Predictive of Severe Forms of COVID-19
Current data in the literature demonstrate that the immune response to CoV-2-SARS is much more complex than initially assumed. In fact, beyond the humoral response, including the existence of neutralizing CAs, the adaptive…
- Trial name
- COVIMMUNITY (NCT04648709)
- Testing
- ELISPOT, QUANTIFERON
- Where
- France
- Volunteers
- 73 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
History of Covid-19, Seroprevalence
Immune Status SARS-CoV-2 in a Sample of a Tertiary Eye Health Centre
A sequential combination of different antibodies test against SARS-CoV-2 is evaluated. The protocol included a rapid test and several ELISA tests within a defined cohort of healthcare workers.
- Trial name
- CovidImmunEye (NCT04446338)
- Testing
- Antibody Test
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
COVID-19, Immunosuppression
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
Immunocompromised individuals, such as solid organ transplant (SOT) recipients are at high risk of COVID-19 associated complications and mortality.
- Conditions
- COVID-19, Immunosuppression, Vaccine Response Impaired
- Trial name
- ADIVKT (NCT05060991)
- Testing
- Reduction in antimetabolite immunosuppression
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, Davis
Arbovirus Disease, Zika
Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu
The Pacific region is facing several emerging and neglected diseases notably mosquito-borne diseases as malaria or arboviroses among which dengue, Ross River, chikungunya and Zika.
- Conditions
- Arbovirus Disease, Zika, Dengue, Ross River
- Trial name
- PIANO (NCT05153018)
- Testing
- Blood collection
- Where
- 4 sites in Vanuatu
- Volunteers
- 1,122 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Lung Cancer, COVID
Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection
Observational, retrospective data collection and prospective IgG analysis, and multicenter study. The main objective of the study is th description of the characteristics and evolution of patients with lung cancer who have…
- Conditions
- Lung Cancer, COVID, Corona Virus Infection
- Trial name
- SOLID (NCT04407143)
- Testing
- IgG test
- Where
- 68 sites in Spain
- Volunteers
- 1,980 people
- Sponsor
- Fundación GECP
Treat and Prevent Covid-19 Infection
Safety and Immunity of Covid-19 aAPC Vaccine
In December 2019, viral pneumonia (Covid-19) caused by a novel beta-coronavirus (SARS-CoV-2) broke out in Wuhan, China. Some patients rapidly progressed and suffered severe acute respiratory failure and died, making it imperative…
- Trial name
- NCT04299724
- Testing
- Pathogen-specific aAPC
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
COVID-19
Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.
In order to investigate whether a germinal center response occurs following vaccine boost and to characterize it based on the type of vaccine received, we aim to analyze Spike and/or RBD-specific germinal center B cells within…
- Trial name
- LymphoBOOST (NCT05951920)
- Testing
- Lymph node aspiration / Blood sampling
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
SARS-CoV2, Covid19
A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults
This study is being conducted to look at the safety and immune response (how the immune system of the human body reacts) to a vaccine for SARS-CoV-2 (the virus responsible for COVID-19 infection) when administered as an…
- Trial name
- NCT04495933
- Testing
- MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg, MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg, MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg
- Where
- Australia
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- The University of Queensland
SARS-CoV2 Infection Common Pathogens, Diabetes Mellitus, Type 1
Characterisation of the Immune Response to SARS-CoV-2 Infection / COVID-19 in Type 1 Diabetes
Emerging clinical details of the current SARS-CoV-2 pandemic have illustrated that there are multiple clinical presentations and outcomes of this viral infection.
- Trial name
- TIRID (NCT05171998)
- Testing
- venous blood sample
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cwm Taf University Health Board (NHS)
Covid-19 Immune Status of Healthcare Workers
Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers
The study objectives were to assess 1/the immune status of healthcare professionals with suggestive symptomatology of Covid-19 infection and 2/the sensitivity and specificity of AAZ rapid test by comparing it with a serological…
- Trial name
- NCT04525417
- Testing
- AAZ Covid-19 rapid test
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
Core Body Temperature in Healthy Subjects, Immune Response to mRNA COVID-19 Vaccination
Fever Tracking Study
The aim of this study is to investigate the feasibility of continuous fever tracking of participants having fever symptoms in a home setting, using a core body temperature (CBT) sensor.
- Trial name
- NCT05475067
- Where
- Switzerland
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland